849459-86-5
Chemical Structure
AC-263093 free base
Synonym(s): AC-093
- CAS No.: 849459-86-5
- Formula:C8H8Br2N4
- Molecular Weight:319.98
IUPAC Name: (E)-2-(3,4-dibromobenzylidene)hydrazine-1-carboximidamide
InChIKey: VMYFCUKMGMFQNH-YIXHJXPBSA-N
SMILES: BrC1=CC=C(/C=N/NC(N)=N)C=C1Br
Biological Activity: AC-263093 free base (AC-093) is a NPFFR2 agonist and a NPFFR1 functional antagonist, with pKi values of 6.9 and 7.0, respectively. AC-263093 free base selectively activates NPFFR2 (and inhibits NPFFR1) coupled to Gai/o proteins, thereby inhibiting adenylyl cyclase to reduce cAMP production. AC-263093 free base can be used for research on depression and anxiety-like disorders, inflammatory and neuropathic pain, and opioid tolerance[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
AC-263093 free base | 99.66% | AC-263093 free base (AC-093) is a NPFFR2 agonist and a NPFFR1 functional antagonist, with pKi values of 6.9 and 7.0, respectively. AC-263093 free base selectively activates NPFFR2 (and inhibits NPFFR1) coupled to Gai/o proteins, thereby inhibiting adenylyl cyclase to reduce cAMP production. AC-263093 free base can be used for research on depression and anxiety-like disorders, inflammatory and neuropathic pain, and opioid tolerance. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Lee H, et al. Renal autocrine neuropeptide FF (NPFF) signaling regulates blood pressure. Scientific reports. 2024 Jul 04;14(1):15407.
- [2]. Lin YT, et al. Chronic activation of NPFFR2 stimulates the stress-related depressive behaviors through HPA axis modulation. Psychoneuroendocrinology. 2016 Sep;71:73-85.
- [3]. Lameh J, et al. Neuropeptide FF receptors have opposing modulatory effects on nociception. The Journal of pharmacology and experimental therapeutics. 2010 Jul;334(1):244-54.
- [4]. Zhang R, et al. Spinal administration of the multi-functional opioid/neuropeptide FF agonist BN-9 produced potent antinociception without development of tolerance and opioid-induced hyperalgesia. European journal of pharmacology. 2020 Aug 05;880:173169.
- [5]. Malin DH, et al. Reversal of morphine tolerance by a compound with NPFF receptor subtype-selective actions. Neuroscience letters. 2015 Jan 01;584:141-5. [Content Brief]
